Alnylam Pharmaceuticals (ALNY) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $231.83, -0.94% vs the prior close of $234.03.
- Volume 1.40M shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ALNY dips 0.9% to $231.83. Closed at $231.83, -0.94% vs the prior close of $234.03. Day range $231.30–$237.98, opened at $235.18.
ALNY daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ALNY dips 0.9% to $231.83
- Closed at $231.83, -0.94% vs the prior close of $234.03. Day range $231.30–$237.98, opened at $235.18.
- Volume was 1.40M shares, 0.9x its 50-day average of 1.51M.
- Price is -2.8% vs its 50-day average ($238.41) and -21.2% vs its 200-day average ($294.30).
- 52-week range $197.81–$495.55; today's close sits at 11% of that range, 53.2% below the 52-week high.
Oct 15, 2026 — ALNY jumps 4.3% to $234.03
- Closed at $234.03, +4.26% vs the prior close of $224.47. Day range $228.12–$234.30, opened at $230.00.
- Volume was 1.26M shares, 0.8x its 50-day average of 1.54M.
- Price is -1.7% vs its 50-day average ($238.10) and -20.7% vs its 200-day average ($295.12).
- 52-week range $197.81–$495.55; today's close sits at 12% of that range, 52.8% below the 52-week high.
Oct 14, 2026 — ALNY ends flat (+0.3%) to $224.47
- Closed at $224.47, +0.29% vs the prior close of $223.82. Day range $222.25–$229.56, opened at $224.49.
- Volume was 1.11M shares, 0.7x its 50-day average of 1.58M.
- Price is -5.7% vs its 50-day average ($237.99) and -24.2% vs its 200-day average ($295.95).
- 52-week range $197.81–$495.55; today's close sits at 9% of that range, 54.7% below the 52-week high.
Oct 13, 2026 — ALNY dips 1.4% to $223.82
- Closed at $223.82, -1.41% vs the prior close of $227.02. Day range $221.56–$229.53, opened at $228.93.
- Volume was 1.12M shares, 0.7x its 50-day average of 1.62M.
- Price is -5.9% vs its 50-day average ($237.88) and -24.6% vs its 200-day average ($296.83).
- 52-week range $197.81–$495.55; today's close sits at 9% of that range, 54.8% below the 52-week high.
Oct 12, 2026 — ALNY dips 2.4% to $227.02
- Closed at $227.02, -2.43% vs the prior close of $232.68. Day range $226.35–$233.60, opened at $233.13.
- Volume was 916.90K shares, 0.5x its 50-day average of 1.69M — lighter than usual.
- Price is -4.5% vs its 50-day average ($237.81) and -23.7% vs its 200-day average ($297.71).
- 52-week range $197.81–$495.55; today's close sits at 10% of that range, 54.2% below the 52-week high.
Oct 9, 2026 — ALNY jumps 3.6% to $232.68, 5 up days in a row
- Closed at $232.68, +3.63% vs the prior close of $224.53. Day range $222.71–$232.94, opened at $224.74.
- Volume was 959.40K shares, 0.5x its 50-day average of 1.87M — lighter than usual.
- Price is -2.0% vs its 50-day average ($237.38) and -22.1% vs its 200-day average ($298.57).
- 52-week range $197.81–$495.55; today's close sits at 12% of that range, 53.0% below the 52-week high.
- That makes 5 straight gains.
Oct 8, 2026 — ALNY ends flat (+0.1%) to $224.53, 4 up days in a row
- Closed at $224.53, +0.05% vs the prior close of $224.41. Day range $218.39–$225.90, opened at $222.03.
- Volume was 1.77M shares, 1.0x its 50-day average of 1.86M.
- Price is -5.2% vs its 50-day average ($236.84) and -25.0% vs its 200-day average ($299.45).
- 52-week range $197.81–$495.55; today's close sits at 9% of that range, 54.7% below the 52-week high.
- That makes 4 straight gains.
Oct 7, 2026 — ALNY ends flat (+0.2%) to $224.41, 3 up days in a row
- Closed at $224.41, +0.21% vs the prior close of $223.94. Day range $222.46–$230.42, opened at $224.39.
- Volume was 1.06M shares, 0.6x its 50-day average of 1.87M — lighter than usual.
- Price is -5.7% vs its 50-day average ($238.08) and -25.3% vs its 200-day average ($300.33).
- 52-week range $197.81–$495.55; today's close sits at 9% of that range, 54.7% below the 52-week high.
- That makes 3 straight gains.
Oct 6, 2026 — ALNY rises 1.8% to $223.94
- Closed at $223.94, +1.84% vs the prior close of $219.89. Day range $217.18–$229.18, opened at $221.02.
- Volume was 1.36M shares, 0.7x its 50-day average of 1.87M.
- Price is -6.4% vs its 50-day average ($239.36) and -25.6% vs its 200-day average ($301.18).
- 52-week range $197.81–$495.55; today's close sits at 9% of that range, 54.8% below the 52-week high.
Oct 5, 2026 — ALNY ends flat (+0.1%) to $219.89
- Closed at $219.89, +0.08% vs the prior close of $219.72. Day range $215.46–$222.08, opened at $218.36.
- Volume was 1.28M shares, 0.7x its 50-day average of 1.87M.
- Price is -8.6% vs its 50-day average ($240.45) and -27.2% vs its 200-day average ($302.02).
- 52-week range $197.81–$495.55; today's close sits at 7% of that range, 55.6% below the 52-week high.
Oct 2, 2026 — ALNY slides 5.0% to $219.72, a 1-month low, 5 down days in a row
- Closed at $219.72, -4.96% vs the prior close of $231.18. Day range $219.40–$231.36, opened at $231.31.
- Volume was 1.66M shares, 0.9x its 50-day average of 1.86M.
- Price is -9.0% vs its 50-day average ($241.49) and -27.5% vs its 200-day average ($302.88).
- 52-week range $197.81–$495.55; today's close sits at 7% of that range, 55.7% below the 52-week high.
- That makes 5 straight losses.
ALNY latest news & SEC filings
Every SEC filing by or about ALNY in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Supran Bryan sold 1,758 shares at $226.88 (≈$398.86K) on Oct 2, 2026; now holds 12,807
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 22, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Greenstreet Yvonne received an award of 107 shares on Sep 19, 2026; now holds 95,802
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 30, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $1.29B (prior year $773.69M) (+66.9% vs Jun 30, 2025)
- Net income: $164.49M (prior year -$72.23M) (swung to profit vs Jun 30, 2025)
- Diluted EPS: $1.21 (prior year -$0.55) (swung to profit vs Jun 30, 2025)
Jul 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade ALNY
- Last results release: Jul 30, 2026 (8-K Item 2.02). Previous ones: Apr 30, 2026, Feb 12, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Oct 29, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.04% (largest 6.3%).
- Liquidity: about 1.23M shares (≈$286.06M) trade per day on average.
- 52-week position: $231.83 vs a range of $197.81–$495.55 (11% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: David E I Pyott sold 1,175 shares on Jun 1, 2026.
- Latest filings: 10-Q Jul 30, 2026; 8-K Jul 30, 2026; 8-K May 27, 2026.
- Share count: 133.81M shares outstanding (Jul 24, 2026), +2.1% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ALNY market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 235.18 | 237.98 | 231.30 | 231.83 | 1.40M |
| Oct 15, 2026 | 230.00 | 234.30 | 228.12 | 234.03 | 1.26M |
| Oct 14, 2026 | 224.49 | 229.56 | 222.25 | 224.47 | 1.11M |
| Oct 13, 2026 | 228.93 | 229.53 | 221.56 | 223.82 | 1.12M |
| Oct 12, 2026 | 233.13 | 233.60 | 226.35 | 227.02 | 916.90K |
| Oct 9, 2026 | 224.74 | 232.94 | 222.71 | 232.68 | 959.40K |
| Oct 8, 2026 | 222.03 | 225.90 | 218.39 | 224.53 | 1.77M |
| Oct 7, 2026 | 224.39 | 230.42 | 222.46 | 224.41 | 1.06M |
| Oct 6, 2026 | 221.02 | 229.18 | 217.18 | 223.94 | 1.36M |
| Oct 5, 2026 | 218.36 | 222.08 | 215.46 | 219.89 | 1.28M |
| Oct 2, 2026 | 231.31 | 231.36 | 219.40 | 219.72 | 1.66M |
| Oct 1, 2026 | 248.21 | 251.71 | 230.06 | 231.18 | 2.02M |
| Sep 30, 2026 | 253.68 | 254.44 | 246.66 | 246.74 | 1.04M |
| Sep 29, 2026 | 254.86 | 257.27 | 251.02 | 254.07 | 786.90K |
| Sep 28, 2026 | 256.28 | 256.60 | 248.12 | 255.36 | 1.15M |
| Sep 25, 2026 | 248.39 | 256.66 | 247.51 | 255.96 | 1.08M |
| Sep 24, 2026 | 246.51 | 251.81 | 245.52 | 249.59 | 933.70K |
| Sep 23, 2026 | 249.99 | 253.81 | 245.34 | 246.51 | 1.48M |
| Sep 22, 2026 | 246.86 | 255.51 | 244.13 | 251.65 | 1.13M |
| Sep 21, 2026 | 240.37 | 247.10 | 237.97 | 244.32 | 1.15M |
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (ALNY) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CAMBRIDGE, MA. Fiscal year ends December 31. SEC CIK 1178670.
ALNY board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Stuart A Arbuckle | Director | May 22, 2026 |
| Dennis A Ausiello | Director | May 22, 2026 |
| Olivier Brandicourt | Director | May 22, 2026 |
| Benjamin Cravatt | Director | Jun 3, 2026 |
| Yvonne Greenstreet | Chief Executive Officer | Sep 22, 2026 |
| Margaret A Hamburg | Director | May 22, 2026 |
| Peter N Kellogg | Director | May 22, 2026 |
| David E I Pyott | Director | Jun 3, 2026 |
| Colleen F Reitan | Director | May 22, 2026 |
| Amy W Schulman | Director | May 22, 2026 |
| Charles Elliott Sigal | Director | May 22, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Mar 6, 2026 |
| Pushkal Garg | EVP Chief R&D | Mar 6, 2026 |
| Yvonne Greenstreet | Chief Executive Officer | Sep 22, 2026 |
| Melissa Mclaughlin | Chief Human Resources Officer | Apr 7, 2026 |
| Jeffrey V. Poulton | EVP, Chief Financial Officer | Mar 6, 2026 |
| Bryan Supran | EVP, CLO and Secretary | Mar 4, 2026 |
| Tolga Tanguler | EVP, Chief Commercial Officer | Mar 6, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 1, 2026 | David E I Pyott | Sale | 1,175 | $298.91 |
| Jun 1, 2026 | David E I Pyott | Sale | 17 | $302.65 |
| Jun 1, 2026 | David E I Pyott | Sale | 921 | $297.71 |
| Jun 1, 2026 | David E I Pyott | Sale | 495 | $300.72 |
| Jun 1, 2026 | David E I Pyott | Sale | 1,222 | $299.87 |
| Jun 1, 2026 | David E I Pyott | Sale | 1,175 | $298.91 |
| Jun 1, 2026 | David E I Pyott | Sale | 17 | $302.65 |
| Jun 1, 2026 | David E I Pyott | Sale | 921 | $297.71 |
| Jun 1, 2026 | David E I Pyott | Sale | 495 | $300.72 |
| Jun 1, 2026 | David E I Pyott | Sale | 1,222 | $299.87 |
| Jun 1, 2026 | David E I Pyott | Sale | 1,175 | $298.91 |
| Jun 1, 2026 | David E I Pyott | Sale | 17 | $302.65 |
| Jun 1, 2026 | David E I Pyott | Sale | 921 | $297.71 |
| Jun 1, 2026 | David E I Pyott | Sale | 495 | $300.72 |
| Jun 1, 2026 | David E I Pyott | Sale | 1,222 | $299.87 |
ALNY financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $3.71B | $313.75M | 2.33 | $524.08M |
| Dec 31, 2024 | $2.25B | $-278.16M | -2.18 | $-8.31M |
| Dec 31, 2023 | $1.83B | $-440.24M | -3.52 | $104.16M |
| Dec 31, 2022 | $1.04B | $-1.13B | -9.30 | $-541.27M |
| Dec 31, 2021 | $844.29M | $-852.82M | -7.20 | $-641.69M |
Latest balance sheet: total assets $5.56B, total liabilities $4.20B, cash $1.71B (as of Jun 30, 2026).
ALNY earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 30, 2026 | 8-K Item 2.02 (results) | $205.48 |
| Apr 30, 2026 | 8-K Item 2.02 (results) | $309.49 |
| Feb 12, 2026 | 8-K Item 2.02 (results) | $308.48 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $370.91 |
| Oct 30, 2025 | 8-K Item 2.02 (results) | $449.56 |
| Jul 31, 2025 | 8-K Item 2.02 (results) | $392.24 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $258.27 |
| Feb 15, 2024 | 8-K Item 2.02 (results) | — |
| Jan 8, 2024 | 8-K Item 2.02 (results) | — |
| Nov 2, 2023 | 8-K Item 2.02 (results) | — |
| Aug 3, 2023 | 8-K Item 2.02 (results) | — |
| May 4, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ALNY
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.